Institute of Cancer Research
|Chancellor||HRH The Princess Royal (University of London)|
|Chief Executive||Professor Paul Workman|
|1,075 (2011 average)|
|Location||London, United Kingdom|
|Student population rank||162nd (of 165)|
|Affiliations||University of London|
The Institute of Cancer Research (the ICR) is a public research institute and university located in London, United Kingdom, specialised in oncology, and a constituent college of the University of London. It was founded in 1909 as a research department of the Royal Marsden Hospital and joined the University of London in 2003. It has been responsible for a number of breakthrough discoveries, including that the basic cause of cancer is damage to DNA.
The ICR occupies two sites, one in Chelsea, Central London and one in Sutton, southwest London, and had a total income of £96.4 million in 2012/13, of which £52.3 million was from peer-reviewed research grant awards. The ICR provides both taught postgraduate degree programmes and research degrees and currently has around 340 students. Together with the Royal Marsden Hospital the ICR forms the largest comprehensive cancer centre in Europe, and was ranked first amongst all British higher education institutions in the Times Higher Education 2014 Research Excellence Framework Table of Excellence. In clinical medicine, 83% and in biological sciences, 96% of the ICR’s academic research was assessed to be world leading or internationally excellent (4* or 3*).
The ICR receives its external grant funding from the government body the Higher Education Funding Council for England, from government research council bodies and from charities including the Wellcome Trust, Cancer Research UK, Breakthrough Breast Cancer and Leukaemia & Lymphoma Research. It also receives voluntary income from legacies and from public and corporate donations. It runs the Everyman Campaign fundraising appeal, which raises awareness of male cancers and funds research into testicular and prostate cancer at the Everyman Centre, which is based at the ICR.
|This section requires expansion. (January 2013)|
The ICR occupies two sites, one in Chelsea, Central London and one in Sutton, southwest London.
The ICR pursues its research focused into three main research themes: genetic epidemiology, molecular pathology, and therapeutic development. These areas of research are essential for the development of personalised cancer medicine.
Towards this aim, the ICR and The Royal Marsden have completed a dedicated £17 million Centre for Molecular Pathology (CMP) which opened on the Sutton site on 20 November 2012. The centre exploits the increasing availability of information about the genetic make-up of different cancer types, in order to design new "personalised" treatments that target cancers' specific molecular defects. The CMP also aims to develop molecular diagnostic techniques that will accurately predict who will benefit most from a treatment, ensuring a patient receives the optimum drug(s) for the best possible outcome. The CMP will build on the organisations' existing expertise in breast, prostate and paediatric cancers, while providing opportunities for new developments in other cancers such as gastrointestinal, renal, gynaecological, melanoma, head & neck cancers and sarcomas.
The ICR has recently started work on a £20 million Centre for Cancer Imaging that will bring together experts in a range of different imaging techniques who will work together developing better cancer diagnostic and treatment techniques. The centre is scheduled to open in Autumn 2014.
The organisation’s research direction is set out in the ICR Scientific Strategy 2010–2015, which aims to develop key research areas while enhancing partnership affiliations. Its four objectives are to maintain, develop and exploit the unique relationship with the Marsden; to ensure a balanced portfolio of basic and applied research; to develop treatment regimes to the genetic makeup of patient and tumour (personalised medicine) and to recruit, retain and motivate the best staff. The ICR also assisted Professor Christopher Nutting and his team at the Royal Marsden Hospital in managing a series of randomised trials using IMRT aimed at reducing the potential side-effects of radiotherapy treatment for head and neck cancers.
The ICR runs an MSc in Oncology programme, which is a modular course aimed primarily at Specialist Registrars in Clinical and Medical Oncology. The course has exit points at Certificate, Diploma and MSc degree level.
1909 to 1970
The ICR was founded in 1909, when a new laboratory building adjoining The Cancer Hospital (later named the Royal Marsden Hospital) was established with Dr Alexander Paine as its first Director. In 1910 Dr Robert Knox was appointed to head the Electrical and Radio-therapeutic Department at The Cancer Hospital and established the first professionally designed X-ray Department for treatment and diagnosis in Britain. The Cancer Hospital Research Institute was officially opened by Prince Arthur, the Duke of Connaught in 1911. In 1921 Professor Archibald Leitch was appointed Director of The Cancer Hospital Research Institute. The Institute became a postgraduate School of the University of London in 1927. In 1931 Professor Sir Ernest Kennaway FRS became Director of the Institute. In 1932 a research team led by Professor Kennaway fractionated coal tar and isolated benzo[a]pyrene, which he identified as one of the chemical constituents that induced cancer in mice. These were the first research findings to show that a pure chemical substance can cause cancer. In 1936 Professor Kennaway proposed the potential of a link between smoking and lung cancer. The Cancer Hospital Research Institute moved to a new site on Fulham Road in Chelsea in 1939 and was renamed the Chester Beatty Research Institute. In 1946 Professor Sir Alexander Haddow FRS became the Director of the Chester Beatty Research Institute. In 1947, while conducting research at the Institute, Professor David Galton became the first physician in the world to use aminopterin (the forerunner of the methotrexate drug) in the treatment of adult leukaemia, producing remission in some cancer patients.
During the 1940s Haddow established a Clinical Chemotherapy Research Unit - the first such unit in Europe - in partnership with the Royal Marsden Hospital and under Galton's leadership. The partnership was unique at the time in being able to take the drug discoveries directly into a partner hospital for clinical trials in cancer patients. The unit led to the Institute's discovery of three successful chemotherapy drugs in the 1950s: busulphan (Myleran), chlorambucil (Leukeran) and melphalan (Alkeran).
In 1952 the ICR's Dr Eric Boyland had proposed that certain chemicals that cause cancer (carcinogens) react with DNA through an alkylation mechanism that damaged the DNA molecule. In follow-up research at the ICR in 1964, Professors Peter Brookes and Philip Lawley proved that chemical carcinogens act by damaging DNA, leading to mutations and the formation of tumours, proving that cancer is a genetic disease based on mutational events.
In 1954 the Institute was officially renamed The Institute of Cancer Research (ICR). The ICR established a second campus in Sutton, Surrey in 1956. Whilst working at the ICR in 1961, Professor Jacques Miller discovered the immunological role of the thymus, as the repository of a special class of lymphocytes (T cells) essential for the mounting of an immune response.
1970 to 2000
Scientists at the ICR were instrumental in the development of one of the world's most widely used anti-cancer drugs, carboplatin (Paraplatin). Carboplatin’s development began in 1970 after scientists in the United States discovered that the platinum-based compound cisplatin was effective against many tumours – but had serious side-effects. A team of ICR and RMH scientists and clinicians including Professors Ken Harrap and Tom Connors, Dr Hilary Calvert and Hospital Consultant Dr Eve Wiltshaw recognised its potential but also the need for a less toxic alternative. In collaboration with the chemical and precious metal company Johnson Matthey plc the ICR scientists evaluated some 300 different platinum-containing molecules and developed a series of second-generation compounds, of which carboplatin was selected as the lead. The first clinical trial of carboplatin was carried out in 1981 and it was launched commercially as Parplatin (manufactured by Bristol-Myers) in 1986. As of 2012 carboplatin is in use for a range of cancers including ovarian and lung. For the development of these platinum-based anticancer drugs the ICR, together with The Royal Marsden Hospital and Johnson Matthey plc, received the Queen’s Award for Technological Achievement in 1991.
During the 1980s ICR scientists including Professors Hilary Calvert, and Ken Harrap and Dr Ann Jackman developed raltitrexed (Tomudex) at the ICR, a drug active for the treatment of colon and other cancers. In 1983 research teams at the Chester Beatty Laboratory of the ICR led by Professors Chris Marshall FRS and Alan Hall FRS discovered N-RAS, one of the first human cancer transforming genes (oncogenes). Professor Alan Hall went on in 1992 to discover that the molecular mechanism for the motility behaviour of animal cells (cell to cell attachment and cell movement) is through control of cytoskeletal assembly by specific GTPase-proteins, known as Rho and Rac. The discovery is of fundamental significance in cancer research since cell motility is a key feature of cancer cell behaviour during metastasis (the spread of tumours around the human body).
In 1994 an ICR team led by Michael Stratton discovered the gene BRCA2, which has been linked to breast cancer, prostate cancer and ovarian cancer. Alan Ashworth’s team in the Breakthrough Breast Cancer Research Centre at the ICR established the connection between mutations in the BRCA2 gene and the operation of DNA repair pathways in cancer cells. This later led to the development of a PARP inhibitor drug, olaparib, which targets the DNA repair pathways of cancer cells. A Phase I trial of olaparib found in June 2009 that tumours shrank or stabilised for more than half of patients with BRCA1 and BRCA2 mutations  It is believed that the drug may also be useful in other patients whose cancer it is linked to an error in their DNA repair pathway.
In 1999 the Chester Beatty Laboratory in Chelsea was redeveloped and extended to incorporate the Breakthrough Toby Robins Breast Cancer Research Centre, which was opened by HRH The Prince of Wales in 1999.
2000 to present
In 2000 Professor Michael Stratton at the ICR initiated the Cancer Genome Project, which was aimed at capitalizing on the knowledge from the Human Genome sequence to screen all human genes in cancer cells to identify those genes responsible for specific cancers. The project was established at the genome sequencing facilities of the Wellcome Trust Sanger Institute near Cambridge, of which Professor Stratton is now the Director. One of the first major achievements of the Cancer Genome Project has been the characterisation of the cancer gene BRAF in collaboration with ICR scientists Professors Chris Marshall and Richard Marais. The research by the ICR team, published in June 2002, revealed that damage to the BRAF gene could cause up to 70 per cent of melanoma skin cancers. This has been instrumental in speeding up the development of new drugs for the treatment of malignant melanoma. Since 2002 the ICR has been working to develop drugs that inhibit BRAF in melanoma and other cancers where the gene is defective.
In the five years from 2004/05, the ICR developed on average two drug development candidates per year. Since 2006, it has licensed three novel series of anti-cancer drugs to major pharmaceutical companies: Hsp90 inhibitors to Novartis, PKB inhibitors to AstraZeneca and PI3Kinase inhibitors to Genentech. The PIl3Kinase inhibitor GDC-0941, licensed to Genentech by Piramed, is thought to have potential in a range of human cancers. In laboratory experiments, ICR scientists found that the drug reduced the growth of glioblastoma (the most common form of brain tumour), it decreased the growth of ovarian tumours and in other studies, it was active against cell lines derived from other human cancers.
In conjunction with The Royal Marsden NHS Foundation Trust, the ICR tested a promising new prostate cancer drug called abiraterone, which it discovered and developed. A randomised placebo-controlled Phase III trial reported in October 2010 that abiraterone could extend survival in some men with late stage prostate cancer. The trial, funded by Janssen Pharmaceutical Companies, included 1,195 patients from 13 countries whose advanced prostate cancer had stopped responding to standard therapies. Abiraterone extended the average overall survival of patients from 10.9 months to 14.8 months compared to a placebo, without many of the unpleasant side-effects associated with conventional chemotherapy. The FDA in April 2011 approved the drug for sale in the US under the trade name Zytiga.
- "The Institute of Cancer Research Annual Report and Financial Statements 2011" (PDF). Institute of Cancer Research. Retrieved 13 April 2012.
- "Page Not Found". Retrieved 16 July 2015.
- "Professor Paul Workman appointed as ICR Chief Executive". Retrieved 16 July 2015.
- "2014/15 Students by HE provider, level, mode and domicile" (XLSX). Higher Education Statistics Agency. Retrieved 19 January 2016.
- "University of London: Colleges/Institutes". Lon.ac.uk. 29 March 2010. Retrieved 29 April 2010.
- "Annual Review 2009" (PDF). Institute of Cancer Research. Retrieved 21 October 2010.
- "Long-term Achievements". Institute of Cancer Research. Retrieved 23 February 2011.
- "Annual Report and Financial Statements for the year ended 31 July 2013" (PDF). Institute of Cancer Research. Retrieved 24 March 2012.
- "Britain's best hospitals: A patients' guide". The Independent. 20 March 2008. Retrieved 20 October 2010.
- "REF 2014 results: table of excellence". Times Higher Education. 18 December 2014. Retrieved 30 December 2014.
- "ICR tops league table of university excellence". Institute of Cancer Research. Retrieved 30 December 2014.
- "The Centre for Molecular Pathology is opened". Icr.ac.uk. Retrieved 20 November 2012.
- "Centre for Cancer Imaging". Icr.ac.uk. Retrieved 24 August 2014.
- "Scientific Strategy". Icr.ac.uk. Retrieved 23 February 2011.
- "Collaboration Yielded A New Class Of Cancer Drugs". Chemical and Engineering News. Retrieved 12 October 2011.
- "Drug discoveries raise profile of cancer chemotherapy". The Institute of Cancer Research's Interactive Education Unit. Retrieved 12 October 2011.
- "Scientific Symposium on Paraplatin" (PDF). Platinum metals review. Retrieved 12 October 2011.
- Wooster, R.; Neuhausen, S.; Mangion, J.; Quirk, Y.; Ford, D.; Collins, N.; Nguyen, K.; Seal, S.; Tran, T.; Averill, D.; Et, A. (1994). "Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13". Science 265 (5181): 2088–2090. doi:10.1126/science.8091231. PMID 8091231.
- Roth, S; Kristo, P; Auranen, A; Shayehgi, M; Seal, S; Collins, N; Barfoot, R; Rahman, N; Klemi, P. J.; Grénman, S; Sarantaus, L; Nevanlinna, H; Butzow, R; Ashworth, A; Stratton, M. R.; Aaltonen, L. A. (1998). "A missense mutation in the BRCA2 gene in three siblings with ovarian cancer". British journal of cancer 77 (8): 1199–202. doi:10.1038/bjc.1998.202. PMC 2150153. PMID 9579822.
- Connor, F; Smith, A; Wooster, R; Stratton, M; Dixon, A; Campbell, E; Tait, T. M.; Freeman, T; Ashworth, A (1997). "Cloning, chromosomal mapping and expression pattern of the mouse Brca2 gene". Human Molecular Genetics 6 (2): 291–300. doi:10.1093/hmg/6.2.291. PMID 9063750.
- Bignell, G; Micklem, G; Stratton, M. R.; Ashworth, A; Wooster, R (1997). "The BRC repeats are conserved in mammalian BRCA2 proteins". Human Molecular Genetics 6 (1): 53–8. doi:10.1093/hmg/6.1.53. PMID 9002670.
- Lancaster, J. M.; Wooster, R; Mangion, J; Phelan, C. M.; Cochran, C; Gumbs, C; Seal, S; Barfoot, R; Collins, N; Bignell, G; Patel, S; Hamoudi, R; Larsson, C; Wiseman, R. W.; Berchuck, A; Iglehart, J. D.; Marks, J. R.; Ashworth, A; Stratton, M. R.; Futreal, P. A. (1996). "BRCA2 mutations in primary breast and ovarian cancers". Nature Genetics 13 (2): 238–40. doi:10.1038/ng0696-238. PMID 8640235.
- Fong, P. C.; Boss, D. S.; Yap, T. A.; Tutt, A; Wu, P; Mergui-Roelvink, M; Mortimer, P; Swaisland, H; Lau, A; O'Connor, M. J.; Ashworth, A; Carmichael, J; Kaye, S. B.; Schellens, J. H.; De Bono, J. S. (2009). "Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers". New England Journal of Medicine 361 (2): 123–34. doi:10.1056/NEJMoa0900212. PMID 19553641.
- "New Drug Targeting Cancer Weakness Shows Great Promise". Icr.ac.uk. 25 June 2009. Retrieved 29 April 2010.
- "Scientists Unravel Crucial Skin Cancer Switch". Icr.ac.uk. Retrieved 29 April 2010.
- Dhomen, N; Reis-Filho, J. S.; Da Rocha Dias, S; Hayward, R; Savage, K; Delmas, V; Larue, L; Pritchard, C; Marais, R (2009). "Oncogenic Braf induces melanocyte senescence and melanoma in mice". Cancer Cell 15 (4): 294–303. doi:10.1016/j.ccr.2009.02.022. PMID 19345328.
-  Archived 29 December 2010 at the Wayback Machine
- "New Drug Blocks Common Cancer Pathway". Icr.ac.uk. 15 July 2009. Retrieved 29 April 2010.
- "Page Not Found". Retrieved 16 July 2015.
- [dead link]
-  Archived 17 June 2011 at the Wayback Machine